TScan Therapeutics's total assets for Q4 2024 were $371.12M, an increase of 6.63% from the previous quarter. TCRX total liabilities were $130.15M for the fiscal quarter, a 9.42% a decrease from the previous quarter. See a summary of the company’s assets, liabilities, and equity.